APOE and Alzheimer disease: Although LCN2 does not show significant differences in mixed dementia, its levels are indeed lower in rapidly progressing AD patients. LCN2 is not significantly associated with CSF biomarkers of neurodegeneration, AD-related pathology, cognitive status, APOE genotype, or the presence of white matter hyperintensities.